{"id":"https://openalex.org/W2103501749","doi":"https://doi.org/10.1158/1535-7163.mct-08-0836","title":"AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts","display_name":"AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts","alternate_titles":[],"publication_year":2009,"publication_date":"2009-07-01","ids":{"openalex":"https://openalex.org/W2103501749","doi":"https://doi.org/10.1158/1535-7163.mct-08-0836","mag":"2103501749","pmid":"https://pubmed.ncbi.nlm.nih.gov/19509270"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.mct-08-0836","doi":"https://doi.org/10.1158/1535-7163.mct-08-0836","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-08-0836","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2103501749"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5103163152","display_name":"Kate F. Byth","orcid":"https://orcid.org/0000-0002-8974-8511","observed_orcids":["https://orcid.org/0000-0002-8974-8511"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kate F. Byth","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101708241","display_name":"Andrew P. Thomas","orcid":"https://orcid.org/0000-0003-3385-8903","observed_orcids":["https://orcid.org/0000-0003-3385-8903"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andrew Thomas","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065006932","display_name":"Gareth D. Hughes","orcid":"https://orcid.org/0000-0002-1938-8039","observed_orcids":["https://orcid.org/0000-0002-1938-8039"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Gareth Hughes","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043026493","display_name":"Cheryl L. Forder","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Cheryl Forder","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051591335","display_name":"Alexandra McGregor","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Alexandra McGregor","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076060851","display_name":"Catherine Geh","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Catherine Geh","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090029622","display_name":"Sandra E. Oakes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Sandra Oakes","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084237572","display_name":"Clive Green","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Clive Green","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112024773","display_name":"Mike Walker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Mike Walker","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086631777","display_name":"Nicholas J. Newcombe","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Nicholas Newcombe","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101922667","display_name":"Stephen A. Green","orcid":"https://orcid.org/0009-0000-5382-7974","observed_orcids":["https://orcid.org/0009-0000-5382-7974"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Stephen Green","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109164243","display_name":"Jim Growcott","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Jim Growcott","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051412228","display_name":"Andy J. Barker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Andy Barker","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5044215747","display_name":"Robert W. Wilkinson","orcid":"https://orcid.org/0000-0001-8180-2643","observed_orcids":["https://orcid.org/0000-0001-8180-2643"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Robert W. Wilkinson","raw_affiliation_strings":["1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom and 2AstraZeneca R&D Boston, Waltham, Massachusetts","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.4527,"has_fulltext":false,"cited_by_count":135,"citation_normalized_percentile":{"value":0.81582737,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":95,"max":100},"biblio":{"volume":"8","issue":"7","first_page":"1856","last_page":"1866"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10583","display_name":"Cancer-related Molecular Pathways","score":0.98580002784729,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.003700000001117587,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.0032999999821186066,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/cyclin-dependent-kinase-inhibitors","display_name":"cyclin-dependent kinase inhibitors","score":0.6499999761581421},{"id":"https://openalex.org/keywords/cdk1","display_name":"CDK1","score":0.8259999752044678},{"id":"https://openalex.org/keywords/cdk2","display_name":"CDK2","score":1.0},{"id":"https://openalex.org/keywords/cdk9","display_name":"CDK9","score":1.0},{"id":"https://openalex.org/keywords/tumor-xenografts","display_name":"tumor xenografts","score":0.8550000190734863},{"id":"https://openalex.org/keywords/cell-cycle-dysregulation","display_name":"cell cycle dysregulation","score":0.843999981880188},{"id":"https://openalex.org/keywords/rb-phosphorylation","display_name":"retinoblastoma protein phosphorylation","score":0.8500000238418579},{"id":"https://openalex.org/keywords/nucleolin","display_name":"nucleolin","score":0.6140000224113464},{"id":"https://openalex.org/keywords/g2-m-cell-cycle-arrest","display_name":"G2/M cell cycle arrest","score":0.7760000228881836},{"id":"https://openalex.org/keywords/dosing-regimen","display_name":"dosing regimen","score":0.6159999966621399},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.640999972820282}],"concepts":[{"id":"https://openalex.org/C124320809","wikidata":"https://www.wikidata.org/wiki/Q46292","display_name":"Cyclin-dependent kinase","level":4,"score":0.7055302858352661},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6597854495048523},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.592913806438446},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.5652937889099121},{"id":"https://openalex.org/C29537977","wikidata":"https://www.wikidata.org/wiki/Q188941","display_name":"Cell cycle","level":3,"score":0.5556532740592957},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.5024542808532715},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.36920690536499023},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3556180000305176},{"id":"https://openalex.org/C1491633281","wikidata":"https://www.wikidata.org/wiki/Q7868","display_name":"Cell","level":2,"score":0.25210291147232056},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.19363370537757874},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002453","descriptor_name":"Cell Cycle","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007093","descriptor_name":"Imidazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D008819","descriptor_name":"Mice, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D011743","descriptor_name":"Pyrimidines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011923","descriptor_name":"Rats, Nude","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014407","descriptor_name":"Tumor Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015153","descriptor_name":"Blotting, Western","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016203","descriptor_name":"CDC2 Protein Kinase","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D016203","descriptor_name":"CDC2 Protein Kinase","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D018844","descriptor_name":"Cyclin-Dependent Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D023041","descriptor_name":"Xenograft Model Antitumor Assays","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D042863","descriptor_name":"Cyclin-Dependent Kinase 9","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D042863","descriptor_name":"Cyclin-Dependent Kinase 9","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D049109","descriptor_name":"Cell Proliferation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D051357","descriptor_name":"Cyclin-Dependent Kinase 2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D051357","descriptor_name":"Cyclin-Dependent Kinase 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1158/1535-7163.mct-08-0836","doi":"https://doi.org/10.1158/1535-7163.mct-08-0836","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1535-7163.mct-08-0836","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":"journal-article"},{"id":"pmid:19509270","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/19509270","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Molecular cancer therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":53,"referenced_works":["https://openalex.org/W86612188","https://openalex.org/W222250376","https://openalex.org/W1876720422","https://openalex.org/W1966975236","https://openalex.org/W1969255091","https://openalex.org/W1973586213","https://openalex.org/W1985826737","https://openalex.org/W1989524887","https://openalex.org/W1990750564","https://openalex.org/W1991054314","https://openalex.org/W1994017228","https://openalex.org/W2002973833","https://openalex.org/W2005173284","https://openalex.org/W2016410910","https://openalex.org/W2017256445","https://openalex.org/W2017898416","https://openalex.org/W2022387751","https://openalex.org/W2025618547","https://openalex.org/W2031136952","https://openalex.org/W2035273416","https://openalex.org/W2040917168","https://openalex.org/W2041254889","https://openalex.org/W2057228860","https://openalex.org/W2058891255","https://openalex.org/W2060334131","https://openalex.org/W2071144955","https://openalex.org/W2075152619","https://openalex.org/W2075750487","https://openalex.org/W2083294658","https://openalex.org/W2084337297","https://openalex.org/W2089258979","https://openalex.org/W2090990735","https://openalex.org/W2095215072","https://openalex.org/W2098203835","https://openalex.org/W2104373322","https://openalex.org/W2104703767","https://openalex.org/W2121619780","https://openalex.org/W2125372689","https://openalex.org/W2127459809","https://openalex.org/W2128102073","https://openalex.org/W2137086876","https://openalex.org/W2150122219","https://openalex.org/W2150755837","https://openalex.org/W2153451248","https://openalex.org/W2153850465","https://openalex.org/W2154626333","https://openalex.org/W2167690964","https://openalex.org/W2172414114","https://openalex.org/W2413116772","https://openalex.org/W3098970458","https://openalex.org/W6639051246","https://openalex.org/W6642477732","https://openalex.org/W6678905531"],"related_works":["https://openalex.org/W2085387015","https://openalex.org/W1985826737","https://openalex.org/W2019465092","https://openalex.org/W2033787418","https://openalex.org/W2889975947","https://openalex.org/W2987340690","https://openalex.org/W2153389501","https://openalex.org/W2779538465","https://openalex.org/W2146673033","https://openalex.org/W2128102073"],"abstract_inverted_index":{"Deregulation":[0],"of":[1,13,42,75,78,140,147,155,163,180],"the":[2,76,138,210,220],"cell":[3,21,67,94,212],"cycle":[4,22,213],"has":[5,219],"long":[6],"been":[7],"recognized":[8],"as":[9,28,38,166],"an":[10,205,225],"essential":[11],"driver":[12],"tumorigenesis,":[14],"and":[15,48,53,86,92,99,217],"agents":[16],"that":[17,152,184,199,214,223],"selectively":[18],"target":[19],"key":[20],"components":[23],"continue":[24],"to":[25,170,192,208,228],"hold":[26],"promise":[27],"potential":[29],"therapeutics.":[30],"We":[31],"have":[32],"developed":[33],"AZD5438,":[34],"a":[35,39,174],"4-(1-isopropyl-2-methylimidazol-5-yl)-2-(4-methylsulphonylanilino)":[36],"pyrimidine,":[37],"potent":[40],"inhibitor":[41],"cyclin-dependent":[43],"kinase":[44],"(cdk)":[45],"1,":[46],"2,":[47],"9":[49],"(IC(50),":[50],"16,":[51],"6,":[52],"20":[54],"nmol/L,":[55],"respectively).":[56],"In":[57,102,134],"vitro,":[58],"AZD5438":[59,118,136,156,218],"showed":[60,151],"significant":[61],"antiproliferative":[62],"activity":[63],"in":[64],"human":[65,120],"tumor":[66,121,126,158],"lines":[68],"(IC(50)":[69],"range,":[70,129],"0.2-1.7":[71],"micromol/L),":[72],"causing":[73],"inhibition":[74,202],"phosphorylation":[77],"cdk":[79,201],"substrates":[80],"pRb,":[81],"nucleolin,":[82],"protein":[83],"phosphatase":[84],"1a,":[85],"RNA":[87],"polymerase":[88],"II":[89],"COOH-terminal":[90],"domain":[91],"blocking":[93],"cycling":[95,142],"at":[96,107],"G(2)-M,":[97],"S,":[98],"G(1)":[100],"phases.":[101],"vivo,":[103,135],"when":[104],"orally":[105],"administered":[106],"either":[108],"50":[109],"mg/kg":[110,115],"twice":[111],"daily":[112,186],"or":[113],"75":[114],"once":[116],"daily,":[117],"inhibited":[119],"xenograft":[122],"growth":[123,127,159],"(maximum":[124],"percentage":[125],"inhibition,":[128],"38-153;":[130],"P":[131],"<":[132],"0.05).":[133],"reduced":[137],"proportion":[139],"actively":[141],"cells.":[143],"Further":[144],"pharmacodynamic":[145],"analysis":[146],"AZD5438-treated":[148],"SW620":[149],"xenografts":[150],"efficacious":[153],"doses":[154],"(>40%":[157],"inhibition)":[160],"maintained":[161],"suppression":[162],"biomarkers,":[164],"such":[165],"phospho-pRbSer(249)/Thr(252),":[167],"for":[168],"up":[169],"16":[171],"hours":[172],"following":[173],"single":[175],"oral":[176,187],"dose.":[177],"A":[178],"comparison":[179],"different":[181],"schedules":[182],"indicated":[183],"chronic":[185],"dosing":[188],"provided":[189],"optimal":[190],"cover":[191],"ensure":[193],"antitumor":[194],"efficacy.":[195],"These":[196],"data":[197],"indicate":[198],"broad":[200],"may":[203],"provide":[204],"effective":[206],"method":[207],"impair":[209],"dysregulated":[211],"drives":[215],"tumorigenesis":[216],"pharmacologic":[221],"profile":[222],"provides":[224],"ideal":[226],"probe":[227],"test":[229],"this":[230],"premise.":[231]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2103501749","counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":14},{"year":2024,"cited_by_count":20},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":4},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":9},{"year":2019,"cited_by_count":9},{"year":2018,"cited_by_count":12},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":8},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":7},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
